New drug combo aims to save kidneys in rare cancer patients who skip surgery

NCT ID NCT05656235

First seen Jan 10, 2026 · Last updated May 13, 2026 · Updated 17 times

Summary

This study tests a combination of two cancer drugs, enfortumab vedotin and pembrolizumab, in 20 people with high-grade upper tract urothelial cancer (a rare cancer of the kidney and ureter). Participants are those who cannot or choose not to have standard surgery to remove the kidney. The goal is to see if the drug combo can control the cancer and preserve kidney function, avoiding the need for surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins University: Sibley Memorial Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.